• JULY 29, 2000

Novartis India: Outpaces industry once again

A 12% growth in the topline has led to a commensurate growth in the bottomline for Novartis India. While the operating margins have improved, higher depreciation has nullified the rise in operating margins.

(Rs m)1QFY001QFY01Change
Sales 1,879 2,106 12.1%
Other Income 53 66 24.5%
Expenditure 1,633 1,824 11.7%
Operating Profit (EBDIT) 246 282 14.6%
Operating Profit Margin (%)13.1%13.4% 
Interest 5 4 -20.0%
Depreciation 28 44 57.1%
Profit before Tax26630012.8%
Other Adjustments   
Tax 100 114 14.0%
Profit after Tax/(Loss) 166 186 12.0%
Net profit margin (%)8.8%8.8% 
No. of Shares (m) (eoy)31.931.9 
Diluted no. of shares (m)31.931.9 
Diluted Earnings per share*20.823.3 

The company has already announced the demerger of the agrichemical business and a 2:1 split (which implies a face value of Rs 5). This would become effective with retrospective effect from April 1, 2000. The current quarter's results however include the operations of the agrichemical division.

Once the split becomes effective the company's operating margins are expected to improve to levels of 16% plus. The inventory and the debtors can also be expected to reduce to levels of around 45 days from the present levels of around 70 days.

The stock quotes at a level of Rs 887 which implies an earning multiple of 38 times FY2001 earnings. The stock has shot up almost 43% in the last two months since the spin off of the agribusiness and 2:1 split was announced.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407